Demographic Characteristics of Participants in Trials Essential to US Food and Drug Administration Vaccine Approvals, 2010-2020
J Gen Intern Med
.
2022 Feb;37(3):700-702.
doi: 10.1007/s11606-021-06670-3.
Epub 2021 Mar 3.
Authors
Audrey D Zhang
1
,
Jeremy Puthumana
2
,
Alexander C Egilman
3
,
Jason L Schwartz
4
,
Joseph S Ross
5
6
7
Affiliations
1
Department of Medicine, Duke University School of Medicine, Durham, NC, USA.
2
Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA.
3
Center for Outcomes Research and Evaluation, Yale-New Haven Health System, New Haven, CT, USA.
4
Department of Health Policy and Management, Yale School of Public Health, New Haven, CT, USA.
5
Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA. joseph.ross@yale.edu.
6
Center for Outcomes Research and Evaluation, Yale-New Haven Health System, New Haven, CT, USA. joseph.ross@yale.edu.
7
Department of Health Policy and Management, Yale School of Public Health, New Haven, CT, USA. joseph.ross@yale.edu.
PMID:
33660209
PMCID:
PMC7928194
DOI:
10.1007/s11606-021-06670-3
No abstract available
Publication types
Letter
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, P.H.S.
MeSH terms
Demography
Drug Approval*
Humans
United States
United States Food and Drug Administration
Vaccines*
Substances
Vaccines
Grants and funding
UL1 TR001863/TR/NCATS NIH HHS/United States
U01 FD005938/FD/FDA HHS/United States
U01 FD004585/FD/FDA HHS/United States
R01 HS022882/HS/AHRQ HHS/United States
R01 HS025164/HS/AHRQ HHS/United States
R01 HL144644/HL/NHLBI NIH HHS/United States